Breast Cancer Clinical Trial

Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer

Summary

The purpose of this study is to measure the safety of the investigational imaging agent, 18F-Var3 and to determine if it is helpful in providing information about how tumor tissues behave.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age 18 years or greater
Biopsy-proven breast malignancy
>/= 1 viable lesion, >/= 1 cm, confirmed on CT, MR, or FDG PET/CT within 4 weeks of protocol enrollment
Newly diagnosed or recurrent disease, on or off therapy
ECOG performance of 0-2 *Note: Lesions are considered viable if they are stable or increasing soft tissue lesions, or if they are FDG-avid bone lesions

Exclusion Criteria:

Life expectancy < 3 months
Pregnancy or lactation
Biopsy or other surgical procedures within 48 hours prior to receiving study intervention
Patients who cannot undergo PT/CT scanning because of weight limits. PET/CT scanners may not be able to function with patients over 400 pounds

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

6

Study ID:

NCT04054986

Recruitment Status:

Completed

Sponsor:

Memorial Sloan Kettering Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Memorial Sloan-Kettering Cancer Center
New York New York, 10065, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

6

Study ID:

NCT04054986

Recruitment Status:

Completed

Sponsor:


Memorial Sloan Kettering Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider